Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 17, 2022

Study Completion Date

June 17, 2022

Conditions
Hepatocellular CarcinomaLiver CancerHepatoma
Interventions
DEVICE

Bead Block microspheres

Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis

OTHER

Bead + Dox Arm

Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Columbia University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00539643 - Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter